Archive

IOP-lowering therapy: current treatment options and future opportunities

Sponsored by Aerie Pharmaceuticals

View Insert

Off Target

Editorially independent content supported with advertising from Novartis

View Insert

A Catalyst for the Development of Glaucoma Therapies

Sponsored by Glaucoma Research Foundation

View Insert

Patient Selection And MIGS Devices for Glaucoma Management

Editorially Independent Content Supported With Advertising by Zeiss and Alcon a Novartis Division

View Insert

Technology Ushers in a New Era of Dramatic Improvements in the Diagnosis and Treatment of Glaucoma

Sponsored by Santen

View Insert

Preventing the Avalanche

Editorially independent content supported with advertising from Alcon a Novartis Division

View Insert

PSLT Lowers IOP with More Comfort Than SLT

Sponsored by Topcon

View Insert

Current and Emerging Glaucoma Therapy: An Update on Disease-Modifying Glaucoma Treatments

View Supplement

The Current Landscape of MIGS Devices for Glaucoma Management

Editorially Independent Content Supported With Advertising by Zeiss and Alcon a Novartis Division

View Supplement

IOP Control in Uncontrolled Glaucoma

Sponsored by Ellex

View Insert

Intravitreal Corticosteroids: Ensuring Effective Use With IOP Control

Supported through an unrestricted educational grant by Allergan

View Supplement

Introducing Aerie Pharmaceuticals in Ophthalmics

View Supplement